European Journal of Clinical Pharmacology

, Volume 31, Issue 2, pp 217–222 | Cite as

Pharmacokinetics of N-acetylcysteine in man

  • L. Borgström
  • B. Kågedal
  • O. Paulsen
Originals

Summary

N-Acetylcysteine was given intravenously and as three fast dissolving and one slow-release formulation, on separate occasions, as a single dose of 600 mg to 10 fasting (5 men and 5 women) healthy volunteers. Blood and urine were sampled for the following 12 h.

Renal clearance constituted around 30% of total body clearance, which was 0.21 l/h/kg. Volume of distribution was 0.33 l/kg, consistent with distribution mainly to extracellular water. The late elimination half-life was 2.27 h and the mean residence time 1.62 h.

The slow-release tablet resulted in a flattened plasma concentration-time curve typical of slow release formulations, while the other three oral formulations were rapidly absorbed.

The oral availability of N-acetylcysteine varied between 6 and 10%, with the slow-release tablet having the lowest and the fast dissolving tablet the highest availability.

Key words

N-acetylcysteine bioavailability slow-release formulation pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sheffner AL (1983) The reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent N-acetyl-L-cysteine. Ann NY Acad Sci 106: 298–310Google Scholar
  2. 2.
    Prescott LF, Illingworth RN, Critchley JAJH, Stewart MJ, Adam RD, Proudfoot AT (1979) Intravenous N-acetylcysteine: The treatment of choice for paracetamol poisoning. Br Med J 2: 1097–1100Google Scholar
  3. 3.
    Myers C, Bonow R, Palmeri S, Jenkins J, Corden B, Locker G, Doroshow J, Epstein S (1983) A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-Acetylcysteine. Semin Oncol 10 [Suppl 1]: 53–55Google Scholar
  4. 4.
    Holoye PY, Duelge J, Hansen RM, Anderson T (1983) Prophylaxis, of ifosfamide toxicity with oral acetylcysteine. Semin Oncol 10 [Suppl 1]: 66–71Google Scholar
  5. 5.
    Botta JA, Nelson LW, Wieker JH Jr (1973) Acetylcysteine in the prevention of cyclophosphamide-induced cystitis in rats. J Natl Cancer Inst 51: 1051–1058Google Scholar
  6. 6.
    Grassi C, Morandi GC (1976) A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis. Eur J Clin Pharmacol 9: 393–396Google Scholar
  7. 7.
    Lemy-Debois N, Frigerio G, Lualdi P (1978) Oral acetylcysteine in bronchopulmonary disease. Comparative clinical trial with bromhexine. Acta Therapeut 4: 125–132Google Scholar
  8. 8.
    Multicenter Study Group (1980) Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study. Eur J Respir Dis 61 [Suppl 111]: 93–108Google Scholar
  9. 9.
    Boman G, Bäcker U, Larsson S, Melander B, Wåhlinder L (1983) Oral acetylcysteine reduces exacerbation rates in chronic bronchitis: Report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis 64: 405–415Google Scholar
  10. 10.
    Rodenstein D, De Coster A, Gazzaniga A (1978) Pharmacokinetics of oral acetylcysteine: Absorption, binding and metabolism in patients with respiratory disorders. Clin Pharmacokinet 3: 247–254Google Scholar
  11. 11.
    Maddock J (1980) Biological properties of acetylcysteine: Assay development and pharmacokinetic studies. Eur J Respir Dis 61 [Suppl 111]: 52–58Google Scholar
  12. 12.
    Morgan LR, Holdiness MR, Gillen LE (1983) N-Acetylcysteine: Its bioavailability and interaction with ifosfamide metabolites. Semin Oncol 10 [Suppl 1]: 56–61Google Scholar
  13. 13.
    Frank H, Thiel D, Langer K (1984) Determination of N-acetyl-L-cysteine in biological fluids. J Chromatogr 309: 261–267Google Scholar
  14. 14.
    Kågedal B, Källberg M, Mårtensson J (1984) Determination of non-protein-bound N-acetylcysteine in plasma by high-performance liquid chromatography. J Chromatogr 311: 170–175Google Scholar
  15. 15.
    Lewis PA, Woodward AJ, Maddock J (1984) High-performance liquid chromatographic assay for N-acetylcysteine in plasma and urine. J Pharm Sci 73 [7]: 996–998Google Scholar
  16. 16.
    Borgström L, Johansson C-G, Larsson H, Lenander R (1981) Pharmacokinetics of bendroflumethiazide after low oral doses. J Pharmacokinet Biopharmaceut 9 [4]: 431–441Google Scholar
  17. 17.
    Kågedal B, Källberg M (1982) Reversed-phase ion-pair high-performance liquid chromatography of mercaptoacetate and N-acetylcysteine after derivatization with N-(1-pyrene)maleimide and N-(7-methylamino-4-methyl-3-coumarinyl)-maleimide. J Chromatogr 229: 409–415Google Scholar
  18. 18.
    Krenzelok EP, North DS, Peterson RG (1980) The effect of activated charcoal administration on N-acetylcysteine serum levels in human subjects. Vet Hum Toxicol 22 [Suppl 2]: 56–58Google Scholar
  19. 19.
    Rowland M, Tozer TN (1980) Clinical pharmacokinetics concepts and applications. Lea & Febiger, Philadelphia, p 50Google Scholar
  20. 20.
    Rowland M, Tozer TN (1980) Clinical pharmacokinetics concepts and applications. Lea & Febiger, Philadelphia, p 149Google Scholar
  21. 21.
    Bonanomi L, Gazzaniga A (1980) Toxicological, pharmacokinetic and metabolic studies on acetylcysteine. Eur J Respir Dis 61 [Suppl 111]: 45–51Google Scholar
  22. 22.
    Sheffner AL, Medler EM, Baily KR, Gallo DG, Mueller AJ, Sarett HP (1966) Metabolic studies with acetylcysteine. Biochem Pharmacol 15: 1523–1535Google Scholar
  23. 23.
    Lauterburg BH, Corcoran GB, Mitchell JR (1983) Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats in vivo. J Clin Invest 71: 980–991Google Scholar
  24. 24.
    Grassi C, Morandini GC, Frigerio G (1973) Clinical evaluation of systemic acetylcysteine by different routes of administration. Curr Ther Res 15: 165–179Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • L. Borgström
    • 1
  • B. Kågedal
    • 2
  • O. Paulsen
    • 3
  1. 1.Research and Development, Pharmacokinetics LaboratoryAB DracoLundSweden
  2. 2.Department of Clinical ChemistryUniversity HospitalLinköpingSweden
  3. 3.Department of Clinical PharmacologyUniversity HospitalLundSweden

Personalised recommendations